• 1. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 5. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylhydrazines
• Other Chemical Reagents

Recent Advances in the Study of 2-Hydroxybenzaldehyde Phenylhydrazone (CAS: 614-65-3) in Chemical Biology and Pharmaceutical Research

2-Hydroxybenzaldehyde Phenylhydrazone (CAS: 614-65-3) is a chemical compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its hydrazone functional group, has been explored for its diverse biological activities, including antimicrobial, anticancer, and anti-inflammatory properties. The unique structural features of 2-Hydroxybenzaldehyde Phenylhydrazone make it a promising candidate for drug development and biochemical studies. This research brief aims to provide an overview of the latest findings related to this compound, highlighting its synthesis, mechanisms of action, and potential therapeutic applications.

Recent studies have focused on the synthesis and optimization of 2-Hydroxybenzaldehyde Phenylhydrazone derivatives to enhance their biological efficacy. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that slight modifications to the phenylhydrazone moiety can significantly alter the compound's binding affinity to target proteins, such as cyclooxygenase-2 (COX-2) and histone deacetylases (HDACs). These findings suggest that 2-Hydroxybenzaldehyde Phenylhydrazone derivatives could serve as potent inhibitors for enzymes involved in inflammation and cancer progression. Additionally, computational modeling and molecular docking studies have provided insights into the structural determinants of its activity, paving the way for rational drug design.

In the context of antimicrobial research, 2-Hydroxybenzaldehyde Phenylhydrazone has shown promising activity against a range of pathogenic bacteria and fungi. A 2022 study in the European Journal of Medicinal Chemistry reported that this compound exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and Candida albicans. The mechanism of action appears to involve disruption of microbial cell membranes and interference with essential metabolic pathways. These results highlight the potential of 2-Hydroxybenzaldehyde Phenylhydrazone as a lead compound for developing novel antimicrobial agents, particularly in the face of rising antibiotic resistance.

Another area of interest is the compound's role in cancer research. Preclinical studies have indicated that 2-Hydroxybenzaldehyde Phenylhydrazone can induce apoptosis in various cancer cell lines, including breast, lung, and colon cancer. Research published in Bioorganic & Medicinal Chemistry Letters (2023) revealed that the compound triggers oxidative stress and mitochondrial dysfunction in cancer cells, leading to programmed cell death. Furthermore, synergistic effects have been observed when 2-Hydroxybenzaldehyde Phenylhydrazone is combined with conventional chemotherapeutic agents, suggesting its potential as an adjunct therapy in oncology.

Despite these promising findings, challenges remain in the development of 2-Hydroxybenzaldehyde Phenylhydrazone-based therapeutics. Issues such as solubility, bioavailability, and potential toxicity need to be addressed through further structural optimization and in vivo studies. Recent advancements in nanotechnology and drug delivery systems offer potential solutions to these challenges, as demonstrated by a 2023 study in the International Journal of Pharmaceutics, which explored the encapsulation of 2-Hydroxybenzaldehyde Phenylhydrazone in polymeric nanoparticles to improve its pharmacokinetic profile.

In conclusion, 2-Hydroxybenzaldehyde Phenylhydrazone (CAS: 614-65-3) represents a versatile and promising compound in chemical biology and pharmaceutical research. Its diverse biological activities, coupled with recent advancements in synthetic and computational approaches, underscore its potential as a therapeutic agent. Future research should focus on addressing the current limitations and exploring its applications in combination therapies and targeted drug delivery systems. This brief highlights the importance of continued investigation into this compound to unlock its full potential in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)